Ann Arbor-based biopharmaceutical company Asalyxa Bio Inc. has closed on a $2 million seed funding round aimed at helping propel the company toward its goal of developing drugs to treat Acute Respiratory Distress Syndrome, or ARDS.The disease affects about 500,000 Americans each year and has been a… -